Compare ARK Innovation ETF (ARKK) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs GSK plc — how do they compare? ARK Innovation ETF trades at $78.17, while GSK plc trades at $52.63 (market cap $103.72B). The key difference: GSK plc pays a 3.4% dividend while ARK Innovation ETF pays none, and GSK plc is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKK | GSK | |
|---|---|---|
52-Week High | $92.50 | $61.18 |
52-Week Low | $63.52 | $36.20 |
Market Cap | — | $103.72B |
Sector | — | Health |
Enterprise Value | — | $124.33B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $80.25, down 1.58% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF has gained about 2% year-to-date through late June, sitting near its pivot point of $81. Recent news highlights Cathie Wood's continued stock purchases during pullbacks while the fund faces criticism for its 0.75% expense ratio and underperformance relative to broader tech markets.
The outlook remains mixed with strong technical momentum but fundamental concerns about fees and concentrated exposure to volatile innovation stocks. Key risks include Tesla's 10% weighting creating single-stock vulnerability and the fund's history of 37.88% losses over five years despite recent investor interest resurgence.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
